DUBLIN , May 12, 2026 /PRNewswire/ --Â Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:
Jazz Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions
From the pullback in refining stock PSX to the breakout in AI pick Corning, here’s what John Rowland is watching ahead of Friday’s livestream.
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
JAZZ Q1 Deep Dive: Oncology and Neuroscience Drive Double-Digit Revenue Growth, Eyes on Upcoming Approvals
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales
– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) –
Barchart Research What to Expect from JAZZ Earnings JAZZ Generated May 4, 2026 Current Price $208.06 EPS Estimate $$3.82 Consensus Rating Strong Buy Average Move 5.67% Jazz Pharmaceuticals' Oncology Pipeline...
Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For